Phase 3 N=485 Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
Ocular Hypertension · Glaucoma
Primary: Intra-Ocular Pressure — -9.67; -9.50 mmHg — p=0.453
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=660 Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Diabetic Macular Edema · Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48 — 8.67; 8.10…
Phase 3 N=56 A Trial to Improve Quality of Life in People With Cirrhosis
Cirrhosis
Primary: Short Form-8 Health Survey (SF-8) at 28 Days — 8.1; 6.55; 70.9; 63.84 score on a scale — p=0.6
Phase 3 N=39 Preoperative Alpha Blockade for Pheochromocytoma
Pheochromocytoma · Paraganglioma
Primary: Hemodynamic Instability — 14; 13 percentage of total operative time — p=.56
Phase 3 N=367 VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
COVID-19
Primary: Number of Participants With Sustained Recovery — 160; 151 Participants
Phase 3 N=100 Topiramate and Prolonged Exposure
PTSD and Alcohol Use Disorder
Primary: CAPS-5 Change — 36.720; 38.600; 21.006; 29.872 score on a scale
Phase 3 N=1,251 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Metastatic Hormone-Sensitive Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as…
Phase 3 N=167 An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Acute Lymphoblastic Leukemia · Lymphoblastic Leukemia
Primary: Response Rate During the First Course of JZP-458 Administration — 18; 70; 44; 20 Participants
Phase 3 N=25 Phase III Copanlisib in Rituximab-refractory iNHL
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE)s — 17; 7; 7; 24 Participants
Phase 3 N=140 A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
Rheumatoid Arthritis
Primary: Number of Subjects With Positive Anti-Drug Antibodies (ADA) on Day 1 — 3; 1 Participants
Phase 3 N=40 Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Marginal Proportion (Expressed as Percentage) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell…
Phase 3 N=377 Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)
Non Cystic Fibrosis Bronchiectasis
Primary: Mean Annual Non-cystic Fibrosis Bronchiectasis (NCFB) Pulmonary Exacerbation Rate — 0.580; 0.948 number of Pulmonary Exacerbations — p=0.00101
Phase 3 N=259 A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Alzheimer's Disease
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity — 20.9; 13.5; 9.2; 19.8 percentage of participants
Phase 3 N=63 Enhancing Adaptations to Exercise
Inflammation
Primary: Change in Maximum Workload Muscle Strength — 7.5; 3.1 pounds
Phase 3 N=80 Bacterial Decolonization to Prevent Radiation Dermatitis
Radiation Dermatitis
Primary: Number of Participants With Incidence of High Grade Radiation Dermatitis — 0; 9 Participants — p=0.004